Modeling of Biological Activity of PEO-Coated Titanium Implants with Conjugates of Cyclic RGD Peptide with Amino Acid Bisphosphonates

Lyudmila V. Parfenova 1,*, Zulfiya R. Galimshina 1, Guzel U. Gil’fanova 1, Eliza I. Alibaeva 1, Ksenia V. Danilko 2, Veta R. Aubakirova 3, Ruzil G. Farrakhov 3, Evgeny V. Parfenov 4 and Ruslan Z. Valiev 4

1 Institute of Petrochemistry and Catalysis, Ufa Federal Research Center, Russian Academy of Sciences, 141, Prospekt Oktyabrya, 450075 Ufa, Russia
2 Central Research Laboratory, Bashkir State Medical University, 3 Lenin Street, 450000 Ufa, Russia
3 Department of Electronic Engineering, Ufa State Aviation Technical University, 12 Karl Marx Street, 450008 Ufa, Russia
4 Department of Materials Science and Physics of Metals, Ufa State Aviation Technical University, 12 Karl Marx Street, 450008 Ufa, Russia
* Correspondence: luda_parfenova@ipc-ras.ru

Abstract: Titanium is considered to be the most essential metal in the field of implantology. The main factors determining metal biocompatibility, among others, include the morphology and chemical composition of the titanium surface. Therefore, the aim of this work was to develop approaches to control the biological activity of the titanium surface by creating coatings that combine both an inorganic phase with a given morphology and organic molecules containing an integrin-selective peptide that regulate cell adhesion and proliferation. As such, we synthesized new c(RGDfC) derivatives of amino acid bisphosphonates (four examples) with different bisphosphonate anchors and maleimide linkers. These molecules were deposited on a highly developed porous surface obtained via the plasma electrolytic oxidation (PEO) of coarse-grained and nanostructured titanium. In vitro studies demonstrated the increase in the viability degree of mesenchymal stem cells and fibroblasts on the surface of coarse-grained or nanostructured titanium modified with PEO and a c(RGDfC) derivative of ε-aminocaproic acid bisphophonate with an SMCC linker. As a result, the use of conjugates of amino acid bisphosphonates with a cyclic RGD peptide for the modification of PEO-coated titanium opens the ways for the effective control of the biological activity of the metal implant surface.

Keywords: titanium implants; biocompatible coatings; c(RGDfC) peptide; bisphosphonic acids; nanostructured titanium; plasma electrolytic oxidation; in vitro tests; mesenchymal stem cells; fibroblasts; MG-63

1. Introduction

Titanium currently retains its position as the most commonly used metal in implantology [1]. Its excellent mechanical strength, chemical stability, and good biocompatibility predetermined the success of its widespread use of titanium and its alloys in this field of medicine. Recent developments led to the application of nanostructured titanium for dental and maxillofacial implants because of its higher strength and biocompatibility compared to commercially available Ti Grade 4 [2]. The quality of a titanium implant surface is one of the key points that contribute to the long-term clinical success of metal device implantation into a bone tissue. Despite the high biocompatibility of titanium, there is a need to solve the problem of a foreign body reaction, which triggers a cascade of biochemical processes preventing successful osseointegration and occasionally causing the device to be rejected [3]. Therefore, the development of methods for modifying the surface of implants
by creating coatings that can provide better biocompatibility and control the response of the bone tissue is an important and topical problem. Moreover, the application of functional coatings on titanium implant surfaces moves the devices to a new generation, because the surface functionalization opens the possibilities to design a biomimetic surface that actively interacts with the extracellular matrix (ECM) [3]. Such a surface requires a coating with physical, chemical, and biological properties that are similar to those of bone; therefore, an inorganic layer with a morphology and phase composition similar to human bone should be used as a substrate in investigations into biologically active functional organic molecules. Such an inorganic layer can be formed on a titanium surface using the plasma electrolytic oxidation technique that has proven itself as an effective method for the development of biocompatible coatings on Ti alloys [4].

To create biologically active coatings, both short peptide sequences and common extracellular matrix proteins (for example, collagen, laminin, fibronectin, and osteopontin) are used. However, regulating the orientation and conformation of adsorbed and grafted large proteins, as well as attaining an appropriate amount of them for effective coating, is a non-trivial task [3]. Moreover, the use of high-molecular-weight ECM proteins is limited due to immunogenicity, difficulty in purification and manipulation, and the risk of pathogen transfer [5]. Therefore, the use of relatively short peptides seems to be more promising. In the mid-1980s, it was shown that many ECM proteins contain an amino acid sequence: arginine–glycine–aspartate (RGD), which binds with the cell surface specific receptors [6]. This discovery preceded the identification of a large group of adhesion receptors, so-called integrins, which specifically recognize the RGD fragment in particular ECM proteins. Integrins interact with ligands and activate intracellular signal transduction pathways serving as an intermediate link in cell migration and adhesion [7]. Integrin functioning significantly affects embryogenesis, angiogenesis, immune system, and tissue development [8].

Currently, there are dozens of short peptide sequences that interact in known ways with various cells. Among them, RGD is most often used for titanium surface modification [9–16]. Other examples of the use of various peptide sequences in combination with antifouling coatings to modify the implant surface are known [17–19].

To modify the surface, along with the use of the linear RGD molecule, the cyclic form of the oligopeptide, as well as the functionalized derivatives of the cyclic RGD fragment (N-methylated and N-acetylated c(RGDfV), phenyl-substituted c(RGD-b-HPhe), c(phg-isODGR-G), etc.) can be applied [20], since cyclic RGD derivatives possess a number of advantages compared to the linear form: they have a higher selectivity for integrins of a certain type (for example, αvβ3 and α5β1) as well as metabolic and enzymatic stability [20–28]. Cyclic peptides c(RGDfK) [29–39] and c(RGDfV) [24,40,41] have previously been used to functionalize the titanium surface to improve osteosynthesis. In some works, a significant acceleration of osteosynthesis and a reduction in the fibrous process along the perimeter of the device in vivo were noted. However, there are rare examples in the literature on the use of cyclic tripeptide c(RGDfC) for the surface modification of titanium implants [41–43], although it is an attractive ligand due to cysteine ending, which can be easily involved in thiol-ene conjugation. Moreover, the cyclic peptide c(RGDfC) is a selective ligand for the ανβ3 integrin [44,45], which plays a significant role in bone tissue biology [46,47].

In our recent study, we carried out the synthesis of linear RGDC peptide conjugates with bisphosphonates of β-alanine, γ-aminobutyric, and ε-aminocaproic acids, which were used as the organic coatings for titanium with the surface modified by plasma electrolytic oxidation (PEO) [48–50]. The presence of gembisphosphonate groups in the molecule increases the degree of their affinity for the oxidized metal surface and gives better solubility in water [51,52]. In vitro studies have shown the promise of these molecules for use as coatings that enhance cell proliferation on the metal surface [48–50].

In continuation of these studies, taking into account the selectivity of cyclic forms of RGD peptide towards integrins and their high enzymatic stability, the aim of this research was to obtain bisphosphonate derivatives and to reveal their ability to influence
the adhesion and viability of cells of various types on the metal surface comprising the effect of the substrate material—commercially available Ti Grade 4 and nanostructured Ti—on the surface’s biological properties.

2. Materials and Methods

2.1. Experimental Design

The experimental design is shown in Figure 1 as a sequence of the sample preparation steps. The experimental design operates with the following factors: substrate structure (2 levels—coarse grained (CG-Ti) commercially available Grade 4 and its nanostructured modification (nano-Ti)), the type of cRGDFC application to the surface (2 levels—adsorbed and anchored), and the structure of compound 6 (4 levels—6a, 6b, 6c, and 6d) for the anchored cRGDFC. In total, this gives a fractional factorial design with 10 combinations.

![Figure 1](https://via.placeholder.com/150)

**Figure 1.** Experimental design scheme showing the steps of the sample preparation.

In detail, the material treatments, sample preparation, and the surface modifications are described below.

2.2. Preparation of Titanium Samples and PEO Coating

Titanium Grade 4 (ASTM F67, chemical composition (wt. %): Fe—0.15, C—0.05, O—0.36, N—0.007, H—0.002, Ti—the rest) was used as the substrate material in this work. Titanium nanostructuring (nano-Ti) was carried out by means of equal-channel angular pressing (ECAP) followed by drawing [53]. As a result of severe plastic deformation, titanium rods with a diameter of 8 mm were obtained. Then, discs 0.5 mm-thick were cut from nano-Ti and CG-Ti rods using spark-cutting EDM equipment. Before the PEO treatment, they were ground by processing on SiC abrasive paper with a grit of 600, 1000, and 2000 to a roughness value of Ra < 0.15 µm. Afterwards, the samples were washed in distilled water and cleaned for 5 min in isopropyl alcohol using an ultrasound bath, before being dried in air at ambient conditions.

Both nano-Ti and CG-Ti sample disks were coated by the plasma electrolytic oxidation (PEO) method in the same processing regime. The PEO coating process was carried out on an automated unit with a capacity of 50 kW, with the program control of the process parameters and maintaining them at a certain level with high accuracy.

Titanium alloy wire (Grade 2) with a diameter of 1 mm was applied as a holder. The titanium disk was placed in an 8 mm loop made at the end of the holder. The current supply was passed along the sample perimeter; the holder itself was also oxidized.

A glass vessel (10 L) equipped with a stainless steel heat exchanger arranged inside the electrolyte (5 L) around the walls was used for the plasma electrolytic oxidation. The PEO processing regime parameters are summarized in Table 1.
Materials 2022, 15, 8120

Table 1. PEO processing regime.

| Electrolyte Composition | Positive Pulse | Negative Pulse |
|-------------------------|----------------|----------------|
|                         | Voltage (V)   | Duty Cycle (%) | Voltage (V) | Duty Cycle (%) | Frequency (Hz) | Temperature (°C) | Duration (min) |
| 20 g/L Na_3PO_4·12 H_2O | 470 ± 5       | 51 ± 0.1       | 40 ± 1      | 26 ± 0.1       | 300 ± 1        | 20 ± 1            | 5′ ± 5″'           |

2.3. Synthesis of Conjugates of cRGD with Amino Acid Bisphosphonates

General Information. The following reagents were used for the synthesis: PCl_3 (98%, Acros Organics, Geel, Belgium), methanesulfonic acid (98%, Acros Organics), maleic anhydride (98%, Acros Organics), β-alanine (97%, Acros Organics), γ-aminobutanoic acid (99%, Acros Organics), ε-aminocaproic acid (98.5%, Merk, Darmstadt, Germany), dicyclohexylcarbodiimide (DCC, 99%, Acros Organics), N-hydroxysuccinimide (98%, Acros Organics), and c(RGDfC) oligopeptide (Cyclo-[Arg-Gly-Asp-D-Phe-Cys]) acetate salt, Bachem, Bubendorf, Switzerland. The N-maleimidosuccinimide linkers (BMPs, EMCS, and SMCC) were obtained according to Refs. [54,55]. The synthesis of maleimides of γ-aminobutyric and ε-aminocaproic acid bisphosphonates 5a–d were carried out according to [49].

Studies of the compound were carried out by means of 1H, 13C, 31P, and two-dimensional NMR (COSY 1H–1H, HSQC 1H–13C, HMBC 1H–13C) on a Bruker Avance II 500 HD Ascend spectrometer (operating frequency 500.17 MHz (1H), 125.78 MHz (13C), and 202.48 MHz (31P)). All the experiments were set up with standard Bruker pulse sequences. D_2O was used as the solvent and internal standard. NMR 31P chemical shifts are given relative to the standard 85% solution of H_3PO_4 in H_2O (δ p p m). The chemical shifts of hydrogen atoms are given in the δ-scale (ppm) with respect to tetramethylsilane (TMS).

General procedure for the synthesis of c(RGDfC) conjugates. The cyclic peptide c(RGDfC) (3 mg, 0.005 mmol) was dissolved in 0.5 mL of bidistilled water, and the pH was adjusted to 7 by adding 0.1 N solution of NaOH. An equivalent amount of compounds 5a–d (0.005 mmol) dissolved in 0.6 mL of water was added to the solution. The reaction mass was stirred for 1–2 h at 38–40 °C, then the solvent was evaporated under reduced pressure. Compounds 6a–d were obtained as a white powder in 87–98% yields.

(c(RGDfC)–BMPS–γ (6a). Yield 4.9 mg (98%). 1H NMR (D_2O) δ: 1.41–1.57 (m, 2H, C_25H_2), 1.61–1.76 (m, 3H, C_3H_2, C_24H_4), 1.78–1.90 (m, 3H, C_3H_2, C_24H_4), 2.31–2.50 (m, 3H, C_3H_2, C_12H_6), 2.54–2.64 (m, 1H, C_13H_4), 2.73–2.83 (m, 2H, C_10H_3, C_11H_3), 2.88–3.05 (m, 2H, C_14H_4), 3.03–3.39 (m, 6H, C_2H_4, C_2H_4, C_11H_4, C_12H_2), 3.44 and 4.12 (both d, J = 5.50 Hz, 2H, C_2H_2), 3.64–3.78 (m, 2H, C_12H_2), 4.20–4.39 (m, 3H, C_1H_3, C_2H_2, C_2H_2), 4.57–4.65 (m, 2H, C_2H_2, C_17H_4), 7.15–7.25 (m, 3H, Ph c(RGDfC)), 7.25–7.33 (m, 2H, Ph c(RGDfC)). 13C NMR (D_2O) δ: 23.59 (C_3), 24.51 (C_20), 26.92 (C_10), 31.42 (C_1), 31.39 (C_5), 31.88 (C_11), 32.84 (C_10), 35.27 (C_6), 35.78 (C_7), 36.32 (C_14), 37.88 (C_18), 40.51 (C_4, C_26), 43.57 (C_21), 50.84 (C_17), 52.74 (C_23), 54.04 (C_12), 54.42 (C_9), 55.10 (C_15), 73.83 (C_1), 127.12 (Ph c(RGDfC)), 128.75 (Ph c(RGDfC)), 129.22 (Ph c(RGDfC)), 136.10 ((Ph c(RGDfC)), 156.65 (C_37), 171.24 (C_16), 172.16 (C_28), 172.66 (C_20), 172.67 (C_22), 173.61 (C_13), 177.97 (C_19). 31P NMR (D_2O) δ: 18.37.

(c(RGDfC)–EMCS–ε (6b). Yield 4.8 mg (89%). 1H NMR (D_2O) δ: 1.12–1.31 (m, 4H, C_4H_2, C_10H_2), 1.38–1.57 (m, 1OH, C_3H_2, C_3H_2, C_3H_2, C_11H_2, C_3H_2), 1.58–1.72 (m, 1H, C_2H_2), 1.74–1.90 (m, 3H, C_2H_2, C_29H_2), 2.09–2.19 (m, 2H, C_3H_2), 2.39–2.49 (m, 1H, C_2H_2), 2.50–2.63 (m, 1H, C_2H_2), 2.74–2.82 (m, 2H, C_14H_4, C_16H_4), 2.88–3.06 (m, 2H, C_20H_2), 3.02–3.12 (m, 2H, C_14H_4, C_16H_4), 3.05–3.19 (m, 4H, C_2H_2, C_31H_2), 3.36–3.51 (m, 3H, C_26H_4, C_12H_2), 4.13 (d, J = 15.0 Hz, 1H, C_1H_3), 4.20–4.30 (m, 1H, C_17H_4), 4.30 (dd, J = 9.50 Hz, J = 5.50 Hz, 1H, C_28H_2), 4.33–4.41 (m, 1H, C_15H_3), 4.46–4.64 (m, 2H, C_19H_2, C_2H_2), 7.15–7.24 (m, 3H, Ph c(RGDfC)), 7.26–7.33 (m, 2H, Ph c(RGDfC)). 13C NMR (D_2O) δ: 24.75 (C_3, C_9, C_11), 25.21 (C_10), 27.04 (C_29), 28.20 (C_5, C_30), 32.45 (C_16), 33.78 (C_7), 35.56 (C_8), 36.27 (C_20), 37.89 (C_23), 38.92 (C_12), 39.41 (C_6, C_31), 41.10 (C_14), 43.73 (C_26), 50.84 (C_22), 52.81 (C_28), 53.80 (C_17), 54.98 (C_15), 55.62 (C_19), 127.05 (Ph c(RGDfC)), 128.86 (Ph c(RGDfC)), 129.23 (Ph c(RGDfC)), 136.11 (Ph c(RGDfC)), 171.78 (C_23), 172.50 (C_21), 172.65 (C_33), 172.83 (C_18, C_27), 176.80 (C_7), 177.87 (C_24). 31P NMR (D_2O) δ: 18.68.
c(RGDfC)–SMCC–γ (6e). Yield 4.9 mg (91%). $^1$H NMR (D$_2$O): δ: 0.87–1.01 (m, 2H, C$_{10}$H$_2$), 1.19–1.34 (m, 2H, C$_{17}$H$_2$), 1.42–1.56 (m, 2H, C$_{28}$H$_2$) 1.56–1.70 (m, 4H, C$_8$H$_2$, C$_9$H, C$_{27}$H), 1.67–1.97 (m, 7H, C$_{12}$H$_2$, C$_{13}$H$_2$, C$_{20}$H$_2$, C$_{27}$H), 2.05–2.16 (m, 1H, C$_6$H), 2.44 (dd, $^3$J = 7.5 Hz, $^2$J = 15.0 Hz, 1H, C$_{21}$H), 2.52–2.61 (m, 1H, C$_{21}$H), 2.73 (dd, $^3$J = 5.0 Hz, $^2$J = 14.0 Hz, 1H, C$_{22}$H), 2.78 (dd, $^3$J = 9.5 Hz, $^2$J = 14.0 Hz, 1H, C$_{14}$H), 2.90–3.06 (m, 5H, C$_{14}$H, C$_{15}$H, C$_{18}$H), 3.07–3.16 (m, 3H, C$_{15}$H, C$_{29}$H$_2$), 3.24–3.36 (m, 2H, C$_{19}$H$_2$), 3.41 and 4.14 (both d, $^2$J = 14.8 Hz, 2H, C$_{24}$H$_2$), 4.25 (dd, $^3$J = 5.0 Hz, $^2$J = 9.0 Hz, 1H, C$_{15}$H), 4.26–4.41 (m, 1H, C$_{16}$H), 4.38–4.47 (m, 1H, C$_{13}$H), 4.51–4.63 (m, 2H, C$_{17}$H, C$_{28}$H), 7.15–7.24 (m, 3H, Ph c(RGDfC)), 7.26–7.33 (m, 2H, Ph c(RGDfC)). $^{13}$C NMR (D$_2$O): δ: 23.48 (C$_3$), 24.45 (C$_{25}$), 27.03 (C$_{27}$), 28.32 (C$_7$), 29.13 (C$_8$), 31.18 (C$_2$), 31.70 (C$_{14}$), 33.24 (C$_{12}$), 35.40 (C$_9$), 36.29 (C$_{18}$), 37.87 (C$_{21}$), 40.49 (C$_4$, C$_{29}$), 43.68 (C$_{24}$), 44.59 (C$_6$), 44.88 (C$_{10}$), 50.83 (C$_{20}$), 52.74 (C$_{26}$), 54.03 (C$_{15}$), 54.55 (C$_{13}$), 55.43 (C$_{17}$), 127.12 (Ph c(RGDfC)), 128.86 (Ph c(RGDfC)), 129.26 (Ph c(RGDfC)), 136.02 (Ph c(RGDfC)), 156.66 (C$_{30}$), 171.26 (C$_{23}$), 172.48 (C$_{19}$, C$_{25}$), 172.61 (C$_{31}$), 177.86 (C$_{22}$). $^{31}$P NMR (D$_2$O): δ: 18.27.

c(RGDfC)–SMCC–ε (6d). Yield 4.8 mg (87%). $^1$H NMR (D$_2$O): δ: 0.87–1.03 (m, 2H, C$_{10}$H$_2$), 1.19–1.39 (m, 4H, C$_{17}$H$_2$, C$_4$H$_2$), 1.42–1.51 (m, 2H, C$_{6}$H$_2$), 1.50–1.57 (m, 2H, C$_{25}$H$_2$), 1.39–1.52 (m, 2H, C$_{30}$H$_2$), 1.51–1.64 (m, 1H, C$_{11}$H), 1.57–1.70 (m, 4H, C$_{16}$H$_2$, C$_{29}$H$_2$), 1.70–1.79 (m, 2H, C$_{23}$H$_2$), 1.76–1.88 (m, 1H, C$_{29}$H), 1.79–1.90 (m, 2H, C$_{22}$H$_2$), 2.03–2.17 (m, 1H, C$_8$H$_2$), 2.45 (dd, $^2$J = 15.8 Hz, $^3$J = 7.3 Hz, 1H, C$_{23}$H), 2.57 (dd, $^2$J = 15.8 Hz, $^3$J = 7.0 Hz, 1H, C$_{23}$H), 2.58–2.69 (m, 2H, C$_{14}$H$_2$), 2.94 (dd, $^2$J = 13.0 Hz, $^3$J = 10.0 Hz, 1H, C$_{20}$H$_2$), 3.03 (dd, $^2$J = 13.0 Hz, $^3$J = 6.0 Hz, 1H, C$_{20}$H$_2$), 3.04–3.19 (m, 4H, C$_{10}$H$_2$, C$_{31}$H$_2$), 3.26–3.33 (m, 2H, C$_{12}$H$_2$), 3.42 and 4.14 (both d, $^2$J = 14.8 Hz, 2H, C$_{23}$H$_2$), 4.12 (dd, $^3$J = 7.6 Hz, $^2$J = 5.2 Hz, 1H, C$_{11}$H), 4.32 (dd, $^3$J = 8.5 Hz, $^2$J = 6.0 Hz, 1H, C$_{20}$H$_2$), 4.55 (dd, $^3$J = 10.0 Hz, $^2$J = 6.0 Hz, 1H, C$_{11}$H), 4.61 (t, $^3$J = 7.0 Hz, 1H, C$_{22}$H), 7.15–7.24 (m, 3H, Ph c(RGDfC)), 7.26–7.33 (m, 2H, Ph c(RGDfC)). $^{13}$C NMR (D$_2$O): δ: 23.40 (C$_3$), 24.52 (C$_{16}$), 26.94 (C$_4$), 27.19 (C$_{29}$), 28.29 (C$_{20}$), 28.57 (C$_3$), 28.59 (C$_9$), 29.17 (C$_{10}$), 33.74 (C$_2$), 37.87 (C$_{23}$), 39.42 (C$_6$), 40.51 (C$_{31}$), 43.70 (C$_{20}$), 44.73 (C$_{12}$), 44.76 (C$_8$), 50.85 (C$_{22}$), 52.72 (C$_{20}$), 55.43 (C$_{19}$), 127.25 (Ph c(RGDfC)), 128.87 (Ph c(RGDfC)), 129.22 (Ph c(RGDfC)), 136.03 (Ph c(RGDfC)), 156.60 (C$_{32}$), 171.21 (C$_{33}$), 172.08 (C$_{25}$), 172.49 (C$_{21}$), 172.69 (C$_{27}$), 173.61 (C$_{18}$), 177.88 (C$_{24}$). $^{31}$P NMR (D$_2$O): δ: 18.62.

2.4. Surface Characterization

The surface morphology of the PEO-coated samples as substrates for the organic coating application was assessed using the Regulus 8220 (Hitachi, Tokyo, Japan) scanning electron microscope (SEM). The visible (surface) coating porosity and average pore size were calculated with ImageJ software from the SEM images according to ASTM E112–10 standard. The PEO coating thickness was measured using Positector 6000 (Defelsko, Ogdensburg, NY, USA) eddy current sensor with N-type gauge. The surface roughness parameters Ra and Rz were measured using TR-220 profilometer (Time High Technology, Beijing, China). The phase constituents of the PEO coating were assessed with X-ray diffractometer Ultima IV, (Rigaku, Tokyo, Japan). The resultant diffractograms were evaluated using Philips XPert software (Philips, Amsterdam, Netherlands); for the quantitative analysis, a semiquantum algorithm embedded into the software was employed.

To characterize the organic part of the coating, X-ray photoelectron spectroscopy (XPS) was carried out using a JEOL JPS 9010MX spectrometer equipped with an (Mg Ka) X-ray source. The spectra were acquired at the pressure less than 7 × 10$^{-8}$ Pa in the analytical chamber. The survey spectra were collected from 0 to 1000 eV with a pass energy of 50 eV, and high-resolution spectra were collected for each detected element of interest (C, N, O, P, S, and Ti) with a pass energy of 10 eV. For the characteristic peak identification, the elemental composition calculations, and the peak fitting in the high-resolution spectra the JEOL SpecSurf Program V. 1.9.2 was used.
2.5. Response of Human Cells to Conjugates of c(RGDfC) with Amino Acid Bisphosphonates and Ti-PEO Coating

Human osteosarcoma cells (MG-63) were obtained from the Russian collection of cell cultures of the Institute of Cytology, Russian Academy of Sciences (Institute of Cytology, St. Petersburg, Russia). Human adipose tissue mesenchymal stem cells (MSCs) and embryonic human lung fibroblasts (FLECH-104) (BIOLOT, St. Petersburg, Russia) were used for in vitro studies as well. MG-63 and FLECH-104 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) (Sigma-Aldrich, Burlington, MA, USA) containing 10% fetal bovine serum (FBS) (BioWest, Nuaillé, France). MSCs were cultured in DMEM with 20% FBS and 1 g/L glucose (Sigma) in a humidified atmosphere with 5% CO\textsubscript{2} in 25 cm\textsuperscript{2} culture flasks (SPL Life Sciences, Pocheon-si, Republic of Korea). The culture medium was changed twice a week. Following monolayer formation, cells were separated using 0.25% trypsin solution (PANECO, Moscow, Russia) and counted by an automatic cell counter TC20 (BioRad, Hercules, CA, USA) and used for further experiments.

The MTT test was used to evaluate the cell viability in culture medium with c(RGDfC) derivatives \textit{6a–d}, which assesses the cell metabolic activity proportional to their number. MSCs (5 × 10\textsuperscript{3}) were seeded into a 96-well culture plate, and when they reached a monolayer, 5 vol% solutions of organic compounds (0.1–0.01 mg/mL) were added to the complete medium, 6 wells of each type were used. Culture medium with only solvents of organic compounds was used as cell viability control. Cells were incubated with organic compounds under standard conditions (5 vol% CO\textsubscript{2}, 37 °C) within 7 days. MSCs in complete culture medium with 5% of the solvent for organic derivatives served as controls. The medium was substituted with an MTT solution (0.5 mg/mL) for 3.5 h, and then with dimethyl sulfoxide to dissolve the formazan crystals formed in the mixture. The plate reader Spark10M (Tecan, Männedorf, Switzerland) was applied to measure the absorbance at 530 nm with a reference wavelength of 620 nm.

A modification of the MTT test, EZ4U (Biomedica), was used to analyze cell proliferation. Ti samples with PEO coating were cleaned in 95% ethanol for 10 min in ultrasonic bath and then washed with deionized water, dried in air atmosphere and autoclaved at 134 °C. For the deposition of organic molecules on the surface of PEO-coated Ti disks, these were kept in a sterile 15 mL centrifuge tube with solutions of organic derivatives in a solvent system of ethanol–DMSO at a ratio of 100:9 with a substance content of 0.1 mg/mL for 1 h. The solutions were pre-sterilized by filtration through the 0.22 µm CA filter. Then, the samples were dried in air and placed in a 48-well culture plate. A suspension of MSC, FLECH-104, or MG-63 cells was placed in the plate (0.4 mL, containing (6–10) × 10\textsuperscript{3} cells) and incubated under standard conditions for 7 days. The number of cells was compared with the control uncoated Ti-PEO samples. The culture plate well (polystyrene) served as the background. After incubation, the samples of each type were transferred to another 48-well plate loaded with 0.4 mL of fresh complete medium. Then, activated EZ4U solution (40 µL) was added to each well and incubated for 3.5 h at 37 °C, 5 vol% CO\textsubscript{2}. The optical absorbance of the solution was analyzed at 450 nm with a reference wavelength of 620 nm. The percentage of EZ4U metabolization was normalized with respect to the Ti-PEO control group.

The mean value and the standard deviation for 6 (MTT) and 3 (EZ4U) optical density measurements were calculated relative to the corresponding control. As the number of repeats was less than 10, we used the Kruskal–Wallis test with subsequent Dunn’s multiple comparisons test (GraphPad Prism, v.6.01) at a significance level of \( p < 0.05 \) was used for data analysis.

3. Results and Discussions

3.1. Surface Properties of the PEO-Coated Ti Disks as Substrates for the cRGDFc Assessment

The PEO coating on CG-Ti and nano-Ti has a porous structure which is beneficial for the cell fixation, as shown elsewhere [7]. As seen from Figure 2 and Table 2, the coating morphology slightly differs between CG-Ti and nano-Ti. The coating on nano-Ti is 15%
thicker, so the roughness Rz appears also higher. The coating porosity value is similar for the both substrates; however, the pore size distribution is different: the PEO coating on nano-Ti (Figure 2a) has numerous smaller pores. As a result, the average pore size is twice lower than that for the CG-Ti. This is consistent with earlier studies [48,56]. Since the pore size affects the ability of cells to attach to the surface, it is expected that these two substrates have different cell responses. As follows from the results of the X-ray diffractometry (Table 2, Figure S1—Supplementary material), the main crystalline constituent of the PEO coating is anatase, which is a lower temperature phase of the titania, and the anatase is more biocompatible than rutile [57]. Larger pores in the PEO coating appear due to larger microdischarges during the process, thus resulting in higher rutile content for the CG-Ti substrate. This dependency was described earlier, and these results are consistent with the previous studies [58].

![SEM images of the top view of the PEO coatings on CG-Ti (a), nano-Ti (b).](image)

Table 2. Properties of the PEO coatings on coarse-grained and nanostructured Ti disks.

| Sample         | h (µm) | Rz (µm) | Ra (µm) | Porosity (%) | Average Pore Size (µm) | Anatase Content (%) | Rutile Content (%) |
|----------------|--------|---------|---------|--------------|------------------------|---------------------|-------------------|
| CG-Ti-PEO      | 18.9 ± 1.1 | 15.6 ± 0.54 | 2.6 ± 0.13 | 7.6 ± 1.4 | 1.44 ± 0.17 | 62 ± 2% | 38 ± 2% |
| Nano-Ti-PEO    | 21.6 ± 1.3 | 17.3 ± 2.54 | 2.5 ± 0.05 | 7.6 ± 1.5 | 0.61 ± 0.11 | 70 ± 2% | 30 ± 2% |

3.2. Synthesis and Biological Properties of the cRGDFC Organic Coatings

We synthesized a set of c(RGDFC) (cyclo(-Arg-Gly-Asp-D-Phe-Cys)) derivatives, in which the peptide fragment was conjugated with γ-aminobutyric and ε-aminocaproic acid bisphosphonates via BMPS, EMSC, and SMCC linkers (Scheme 1). For this purpose, we preliminarily obtained N-maleimides of γ-butyric and ε-caproic acids bisphosphonates (5a–d) according to our previously developed procedure [49]. The conjugation of compounds 5a–d with c(RGDFC) was carried out via Michael addition in an aqueous medium at 38–40 °C, as a result of which compounds 6a–d were observed (Scheme 1).

The structures of compounds 6a–d were proven using one- (1H, 13C, 31P) and two-dimensional (COSY HH, HSQC, and HMBC) NMR spectroscopy. The 1H NMR spectra showed signals corresponding to c(RGDFC), linker, and aminobisphosphonate fragments (Supplementary material, Figures S2–S5). The only resonance lines at δH 17–18 ppm in the 31P NMR spectra indicated the presence of the bisphosphonate group in the molecules. The addition of c(RGDFC) to 5a–d led to the disappearance of the signal at δH 6–7 ppm corresponding to the N-maleimide double bond fragment.
The occurrence of organic molecules in the porous PEO sublayer was established by X-ray photoelectron spectroscopy (XPS). Peaks of Ti2p, Ti3s, O1s, C1s, P2p, N1s, and S2s were observed in the XPS spectra (Figure 3). XPS analysis of the c(RGDfC)-modified samples showed changes in the chemical composition of the surface compared to the sample without an organic coating. The greatest differences were found for the Ti2p, C1s, O1s, and N1s peaks. The appearance of the organic compounds provided the decrease in the Ti2p line intensity and the increase in the C1s', O1s', and N1s' intensity, which corresponded to a decrease in the Ti2p/C1s, Ti2p/O1s, and Ti2p/N1s ratios compared to the control (Table 3).

Scheme 1. Reaction conditions: a. PCl3, MeSO3H, 85–90 °C, 4–5 h; b. H2O:acetone = 1:1, pH = 8–9, r.t., 1 h; c. c(RGDfC), H2O, pH = 7, 38–40 °C, 1–1.5 h.

Figure 3. Survey XPS spectra of the CG-Ti-PEO-6d coating.
Table 3. Atomic composition and ratio for the Ti-PEO samples obtained from XPS high-resolution spectra.

| Sample       | Atomic Composition (%) | Atomic Ratio |
|--------------|------------------------|--------------|
|              | Ti2p | O1s | C1s | N1s | P2p | S2s | Ti2p/O1s | Ti2p/C1s | Ti2p/N1s |
| -            |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 11.70 | 60.70 | 20.45 | 0.79 | 2.47 | 0.00 | 0.19 | 0.57 | 14.81 |
| Nano-Ti-PEO  | 9.78  | 58.38 | 25.36 | 0.95 | 2.45 | 0.00 | 0.17 | 0.39 | 10.29 |
| c(RGDfC)     |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 5.50  | 67.42 | 22.78 | 0.54 | 1.63 | 0.00 | 0.08 | 0.24 | 10.19 |
| Nano-Ti-PEO  | 4.07  | 76.25 | 17.19 | 0.40 | 0.57 | 0.00 | 0.05 | 0.24 | 10.18 |
| 6a           |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 0.89  | 76.00 | 21.90 | 0.26 | 0.78 | 0.00 | 0.01 | 0.04 | 3.42  |
| Nano-Ti-PEO  | 5.59  | 70.58 | 20.16 | 0.65 | 1.28 | 0.00 | 0.08 | 0.28 | 8.60  |
| 6b           |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 4.65  | 69.48 | 22.66 | 0.68 | 0.82 | 0.20 | 0.07 | 0.21 | 6.84  |
| Nano-Ti-PEO  | 3.46  | 68.09 | 23.27 | 0.55 | 0.47 | 0.31 | 0.05 | 0.14 | 6.29  |
| 6c           |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 9.08  | 70.59 | 14.44 | 0.71 | 2.01 | 0.11 | 0.13 | 0.63 | 12.79 |
| Nano-Ti-PEO  | 3.10  | 68.35 | 25.95 | 0.56 | 0.31 | 0.32 | 0.05 | 0.12 | 5.54  |
| 6d           |      |     |     |     |     |     |          |          |          |
| CG-Ti-PEO    | 6.28  | 68.19 | 19.52 | 2.28 | 1.15 | 0.24 | 0.09 | 0.32 | 2.75  |
| Nano-Ti-PEO  | 6.39  | 68.66 | 20.26 | 0.65 | 1.32 | 0.00 | 0.09 | 0.32 | 9.83  |

In vitro studies of the viability and proliferation of mesenchymal stem cells, fibroblasts, and osteoblast-like cells (MG-63) demonstrated the dependence of the biological activity on the structure of the molecules introduced into the PEO-modified surface of nano- and CG-Ti samples (Figures 4 and 5a–c). The evaluation of the cell viability with c(RGDfC) and its derivatives 6a–d in culture medium showed a decrease of up to 40% for the unmodified c(RGDfC) (Figure 4), while the appearance of a linker and a bisphosphonate group in the structure overcame this problem.

![Figure 4](image-url)  
**Figure 4.** Cell viability established by the MTT test in the presence of compounds. Significant differences with the control ($p < 0.05$) are shown with asterisks.

There is the same effect of the reduction in the degree of viability of all the studied cell types on the Ti-PEO surface containing the c(RGDfC) peptide (Figure 5a–c). The appearance of molecules 6b and 6c in the composition of the surface also reduced the proliferation of osteoblast-like cells MG-63 and MSCs. This effect is likely due to toxicity of RGD and some of its derivatives and may be related to the known effect of cell death via the apoptotic pathway as a result of exposure to these molecules [59,60].
Figure 4. Cell viability established by the MTT test in the presence of compounds. Significant differences with the control ($p < 0.05$) are shown with asterisks. There is the same effect of the reduction in the degree of viability of all the studied cell types on the Ti-PEO surface containing the c(RGDfC) peptide (Figure 5a–c). The appearance of molecules 6b and 6c in the composition of the surface also reduced the proliferation of osteoblast-like cells MG-63 and MSCs. This effect is likely due to toxicity of RGD and some of its derivatives and may be related to the known effect of cell death via the apoptotic pathway as a result of exposure to these molecules [59,60].

Using the organic molecule 6d with the SMCC linker and $\varepsilon$-aminocaproic acid bisphosphonate fragment (Ti-PEO-6d) in combination with PEO-modified coarse-grained Ti (Figure 5b) provided a significant (up to 30–40%) increase in the fibroblast proliferation. The same molecule caused 20% growth in MSCs on the surface of nanostructured titanium (Figure 5c).

Figure 5. EZ4U in vitro assay of the growth of MG-63 osteoblasts (a), FLECH-104 fibroblasts (b), and adipose-derived MSCs (c) cultivated within 7 days on Ti-PEO samples coated with compounds c(RGDfC), 6a–d. Significant differences with the control ($p < 0.05$) are shown with asterisks.

4. Conclusions

New conjugates of the c(RGDfC) peptide with amino acid bisphosphonates were synthesized. Compounds can be introduced into the pores of the PEO-coated Ti via physicochemical adsorption from solutions. In vitro studies on the proliferation and viability of fibroblasts, mesenchymal stem cells, and osteoblast-like cells have shown the dependence of the biological activity of molecules on its structure. It was shown that c(RGDfC) itself reduces cell viability, and it is apparently toxic. This effect most likely determined the decrease in the degree of proliferation of all cell types studied by us on the Ti surface containing the original peptide. The appearance of a linker and a bisphosphonate anchor in the structure reduced the toxicity of cyclo-RGD, but only the $\varepsilon$-aminocaproic acid derivative with an SMCC linker was able to increase the degree of fibroblasts and mesenchymal stem cell proliferation on the surface of CG or nanostructured titanium. Thus, the use of the integrin-active peptide of cyclic structure makes it possible to effectively control the biological activity of the titanium surface, and the structure of the bisphosphonate anchor and linker as well as the type of metal substrate is of great importance.
Using the organic molecule 6d with the SMCC linker and ε-aminocaproic acid bisphosphonate fragment (Ti-PEO-6d) in combination with PEO-modified coarse-grained Ti (Figure 5b) provided a significant (up to 30–40%) increase in the fibroblast proliferation. The same molecule caused 20% growth in MSCs on the surface of nanostructured titanium (Figure 5c).

4. Conclusions

New conjugates of the c(RGDfC) peptide with amino acid bisphosphonates were synthesized. Compounds can be introduced into the pores of the PEO-coated Ti via physicochemical adsorption from solutions.

In vitro studies on the proliferation and viability of fibroblasts, mesenchymal stem cells, and osteoblast-like cells have shown the dependence of the biological activity of molecules on its structure. It was shown that c(RGDfC) itself reduces cell viability, and it is apparently toxic. This effect most likely determined the decrease in the degree of proliferation of all cell types studied by us on the Ti surface containing the original peptide. The appearance of a linker and a bisphosphonate anchor in the structure reduced the toxicity of cyclo-RGD, but only the ε-aminocaproic acid derivative with an SMCC linker was able to increase the degree of fibroblasts and mesenchymal stem cell proliferation on the surface of CG or nanostructured titanium. Thus, the use of the integrin-active peptide of cyclic structure makes it possible to effectively control the biological activity of the titanium surface, and the structure of the bisphosphonate anchor and linker as well as the type of metal substrate is of great importance.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ma15228120/s1, Figures S1–S5: XRD, 1H, 13C, 31P and COSY HH NMR of compounds 6a–d.

Author Contributions: Conceptualization, L.V.P. and E.V.P.; methodology, Z.R.G., V.R.A. and K.V.D.; validation, L.V.P., K.V.D. and E.V.P.; formal analysis, R.Z.V.; investigation, Z.R.G., G.U.G., E.I.A., V.R.A., R.G.F. and K.V.D.; resources, L.V.P. and E.V.P.; data curation, L.V.P. and E.V.P.; writing—original draft preparation, Z.R.G. and G.U.G.; writing—review and editing, L.V.P., E.V.P. and K.V.D.; visualization, Z.R.G., R.G.F. and K.V.D.; supervision, L.V.P. and E.V.P.; project administration, L.V.P.; funding acquisition, L.V.P. All authors have read and agreed to the published version of the manuscript.

Funding: The studies were carried out in accordance with the Federal Programs of Ministry of Science and Higher Education of Russian Federation No. FMRS-2022-0081 and FMRS-2022-0074.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The structural studies of compounds 6a–d were carried out on unique equipment at the ‘Agidel’ Collective Usage Center (Ufa Federal Research Center, Russian Academy of Sciences). The titanium nanostructuring and Ti-PEO surface characterization was performed at the Center of Collective Usage of Scientific Equipment “Nanotech” at Ufa State Aviation Technical University, and this support is acknowledged with gratitude.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Geetha, M.; Singh, A.K.; Asokamani, R.; Gogia, A.K. Ti based biomaterials, the ultimate choice for orthopaedic implants—A review. Prog. Mater. Sci. 2009, 54, 397–425. [CrossRef]
2. Valiev, R.Z.; Sabirov, I.; Zemtsova, E.G.; Parfenov, E.V.; Dluhoš, L.; Lowe, T.C. Nanostructured commercially pure titanium for development of miniaturized biomedical implants. In Titanium in Medical and Dental Applications; Froes, F.H., Qian, M., Eds.; Woodhead Publishing: Sawston, UK, 2018; pp. 393–417. [CrossRef]
3. Meyers, S.R.; Grinstaff, M.W. Biocompatible and bioactive surface modifications for prolonged in vivo efficacy. Chem. Rev. 2012, 112, 1615–1632. [CrossRef] [PubMed]
4. Aliofkhazraei, M.; Macdonald, D.D.; Matykina, E.; Parfenov, E.V.; Egorkin, V.S.; Curran, J.A.; Troughton, S.C.; Sinbryukhov, S.L.; Gnedenkov, S.V.; Lampke, T.; et al. Review of plasma electrolytic oxidation of titanium substrates: Mechanism, properties, applications and limitations. *Appl. Surf. Sci.* 2021, 5, 100121. [CrossRef]

5. Reyes, C.D.; Petrie, T.A.; Burns, K.L.; Schwartz, Z.; Garcia, A.J. Biomolecular surface coating to enhance orthopaedic tissue healing and integration. *Biomaterials* 2007, 28, 3228–3235. [CrossRef]

6. Ruoslahti, E. RGD and other recognition sequences for integrins. *Annu. Rev. Cell Dev. Biol.* 1996, 12, 697–715. [CrossRef]

7. Von der Mark, K.; Park, J.; Bauer, S.; Schmuki, P. Nanoscale engineering of biomimetic surfaces: Cues from the extracellular matrix. *Cell Tissue Res.* 2010, 339, 131–153. [CrossRef]

8. Silva, R.; D’Amico, G.; Hodivala-Dilke, K.M.; Reynolds, L.E. Integrins: The keys to unlocking angiogenesis. *Arterioscler. Thromb. Vasc. Biol.* 2008, 28, 1703–1713. [CrossRef]

9. Ferris, D.M.; Moodie, G.D.; Dimond, P.M.; Giorani, C.W.D.; Ehrlich, M.G.; Valentini, R.F. RGD-coated titanium implants stimulate increased bone formation in vivo. *Biomaterials* 1999, 20, 2323–2331. [CrossRef]

10. Jurczak, P.; Witkowska, J.; Rodziewicz-Motowidło, S.; Lach, S. Proteins, peptides and peptidomimetics as active agents in implant surface functionalization. *Adv. Colloid Interface Sci.* 2020, 276, 102083. [CrossRef]

11. Seemann, A.; Akbaba, S.; Buchholz, J.; Türkkan, S.; Tezcaner, A.; Woche, S.K.; Guggenberger, G.; Dräger, G. RGD-Modified Titanium as an Improved Osteoinductive Biomaterial for Use in Dental and Orthopedic Implants. *Bioconjug. Chem.* 2022, 33, 294–300. [CrossRef]

12. Elmengaard, B.; Bechtold, J.E.; Søballe, K. In vivo study of the effect of RGD treatment on bone ongrowth on press-fit titanium alloy implants. *Biomaterials* 2005, 26, 3521–3526. [CrossRef] [PubMed]

13. Rammelt, S.; Illert, T.; Bierbaum, S.; Schneiders, W. Coating of titanium implants with collagen, RGD peptide and chondroitin sulfate. *Biomaterials* 2006, 27, 5561–5571. [CrossRef] [PubMed]

14. Beuvelot, J.; Portet, D.; Lecollinet, G.; Moreau, M.F.; Basié, M.F.; Chappard, D.; Libouban, H. In vitro kinetic study of growth and mineralization of osteoblast-like cells (Saos-2) on titanium surface coated with a RGD functionalized bisphosphonate. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2009, 90, 873–881. [CrossRef] [PubMed]

15. Barber, T.A.; Ho, J.E.; De Ranieri, A.; Virdi, A.S.; Sumner, D.R.; Healy, K.E. Peri-implant bone formation and implant integration strength of peptide-modified p(AAM-co-EG/AAC) interpenetrating polymer network-coated titanium implants. *J. Biomed. Mater. Res. Part A* 2007, 80, 306–320. [CrossRef]

16. Ho, J.E.; Barber, T.A.; Virdi, A.S.; Sumner, D.R.; Healy, K.E. The effect of enzymatically degradable IPN coatings on peri-implant bone formation and implant fixation. *J. Biomed. Mater. Res. Part A* 2007, 81, 720–727. [CrossRef]

17. Costa, B.; Martinez-de-Tejada, G.; Gomes, P.A.C.; Martins, M.C.L.; Costa, F. Antimicrobial Peptides in the Battle against Orthopedic Implant-Related Infections: A Review. *Pharmaceutics* 2021, 13, 1918. [CrossRef]

18. Chen, C.; Kong, X.; Zhang, S.M.; Lee, I.S. Immobilizing osteogenic growth peptide with and without fibronectin on a titanium surface: Effects of loaded proteins on mesenchymal stem cell differentiation. *Int. J. Nanomed.* 2014, 10, 283–295. [CrossRef]

19. Chen, C.; Kong, X.; Zhang, S.-M.; Lee, I.-S. Characterization and in vitro biological evaluation of mineral/osteogenic growth peptide nanocomposites synthesized biomimetically on titanium. *Appl. Surf. Sci.* 2015, 334, 62–68. [CrossRef]

20. Mas-Moruno, C.; Fraioli, R.; Rechenmacher, F.; Neubauer, S.; Kapp, T.G.; Kessler, H. αβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating. *Angew. Chem. Int. Ed. Engl.* 2006, 55, 7048–7067. [CrossRef]

21. Kessler, H. Conformation and Biological Activity of Cyclic Peptides. *Angew. Chem. Int. Ed. Engl.* 1992, 21, 512–523. [CrossRef]

22. Haubner, R.; Grattas, R.; Diefenbach, B.; Goodman, S.L.; Jonczyk, A.; Kessler, H. Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists. *J. Am. Chem. Soc.* 1996, 118, 7461–7472. [CrossRef]

23. Kapp, T.G.; Rechenmacher, F; Neubauer, S.; Maltese, O.V.; Cavalcanti-Adami, E.A.; Zarka, R.; Reuning, U.; Notni, J.; Wester, H.J.; Mas-Moruno, C.; et al. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. *Sci. Rep.* 2017, 7, 39805. [CrossRef] [PubMed]

24. Verrier, S.; Pallu, S.; Bareille, R.; Jonczyk, A.; Meyer, J.; Dard, M.; Amédée, J. Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process. *Biomaterials* 2002, 23, 585–596. [CrossRef]

25. Roxin, A.; Zheng, G. Flexible or fixed: A comparative review of linear and cyclic cancer-targeting peptides. *Future Med. Chem.* 2012, 4, 1601–1618. [CrossRef]

26. Bogdanowich-Knipp, S.J.; Chakrabarti, S.; Williams, T.D.; Dillman, R.K.; Siahaan, T.J. Solution stability of linear vs. cyclic RGD peptides. *J. Pept. Res. Off. J. Am. Pept. Soc.* 1999, 53, 540–541. [CrossRef]

27. Jois, S.D.; Tamburan, U.S.; Chakrabarti, S.; Siahaan, T.J. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation. *J. Biomol. Struct. Dyn.* 1996, 14, 1–11. [CrossRef]

28. Auzzas, L.; Zanardi, F.; Battistini, L.; Burreddu, P.; Carta, P.; Rassu, G.; Curti, C.; Casiraghi, G. Targeting αβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides. *Curr. Med. Chem.* 2010, 17, 1255–1299. [CrossRef]

29. Kantlehner, M.; Schaffner, P.; Finsinger, D.; Meyer, J.; Jonczyk, A.; Diefenbach, B.; Nies, B.; Hölzemann, G.; Goodman, S.L.; Kessler, H. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. *ChemBioChem* 2000, 1, 107–114. [CrossRef]
30. Oliver-Cervelló, L.; Martin-Gómez, H.; Mandakhbayar, N.; Jo, Y.-W.; Cavalcanti-Adam, E.A.; Kim, H.-W.; Ginebra, M.-P.; Lee, J.-H.; Mas-Murono, C. Mimicking Bone Extracellular Matrix: From BMP-2-Derived Sequences to Osteogenic-Multifunctional Coatings. *Adv. Healthc. Mater.* 2022, 2022, 20221399. [CrossRef]

31. Auernheimer, J.; Zúkowska, D.; Dahmen, C.; Kantlehner, M.; Enderle, A.; Goodman, S.L.; Kessler, H. Titanium Implant Materials with Improved Biocompatibility through Coating with Phosphate-Anchored Cyclic RGD Peptides. *ChemBioChem* 2005, 6, 2034–2040. [CrossRef]

32. Mas-Murono, C.; Dorffner, P.M.; Manzenrieder, F.; Neubauer, S.; Reuning, U.; Burgkart, R.; Kessler, H. Behavior of primary human osteoblasts on trimmed and sandblasted Ti6Al4V surfaces functionalized with integrin αvβ3-selective cyclic RGD peptides. *J. Biomed. Mater. Res. Part A* 2013, 101A, 87–97. [CrossRef] [PubMed]

33. Pagel, M.; Meier, R.; Braun, K.; Wiessler, M.; Beck-Sickinger, A.G. On-resin Diels-Alder reaction with inverse electron demand: An efficient ligation method for complex peptides with a varying spacer to optimize cell adhesion. *Org. Biomol. Chem.* 2016, 14, 4809–4816. [CrossRef] [PubMed]

34. Herranz-Diez, C.; Mas-Murono, C.; Neubauer, S.; Kessler, H.; Gil, F.J.; Pegueroles, M.; Manero, J.M.; Guillem-Marti, J. Tuning Mesenchymal Stem Cell Response onto Titanium–Niobium–Hafnium Alloy by Recombinant Fibronectin Fragments. *ACS Appl. Mater. Interfaces* 2016, 8, 2517–2525. [CrossRef] [PubMed]

35. Jäger, M.; Böge, C.; Janissen, R.; Rohrbeck, D.; Hülsen, T.; Lensing-Höhn, S.; Krauspe, R.; Herten, M. Osteoblastic potency of bone marrow cells cultivated on functionalized biomaterials with cyclic RGD-peptide. *J. Biomed. Mater. Res. Part A* 2013, 101A, 2905–2914. [CrossRef] [PubMed]

36. Auernheimer, J.; Kessler, H. Benzylprotected aromatic phosphonic acids for anchoring peptides on titanium. *Bioorg. Med. Chem. Lett.* 2006, 16, 271–273. [CrossRef] [PubMed]

37. Elmengaard, B.; Bechtold, J.E.; Seballe, K. In vivo effects of RGD-coated titanium implants inserted in two bone-gap models. *J. Biomed. Mater. Res. Res.* 2005, 75A, 249–255. [CrossRef]

38. Roessler, S.; Born, R.; Scharnweber, D.; Worch, H.; Sewing, A.; Dard, M. Biomimetic coatings functionalized with adhesion peptides for dental implants. *J. Mater. Sci. Mater. Med.* 2001, 12, 871–877. [CrossRef]

39. Dard, M.; Sewing, A.; Meyer, J.; Verrier, S.; Roessler, S.; Scharnweber, D. Tools for tissue engineering of mineralized oral structures. *Clin. Oral Investig.* 2000, 4, 126–129. [CrossRef]

40. Joner, M.; Cheng, Q.; Schönhofer-Merl, S.; Lopez, M.; Neubauer, S.; Mas-Murono, C.; Lauffer, B.; Kolodige, F.D.; Kessler, H.; Virmani, R. Polymer-free immobilization of a cyclic RGD peptide on a nitinol stent promotes integrin-dependent endothelial coverage of strut surfaces. *J. Biomed. Mater. Res. Part B* 2012, 100B, 637–645. [CrossRef]

41. Tátrai, P.; Sági, B.; Szigeti, A.; Szabó, I.; Bösze, S.; Kristóf, Z.; Markó, K.; Szakács, G.; Urbán, I.; Mezö, G.; et al. A novel cyclic RGD-containing peptide polymer improves serum-free adhesion of adipose tissue-derived mesenchymal stem cells to bone implant surfaces. *J. Mater. Sci. Mater. Med.* 2013, 24, 479–488. [CrossRef]

42. Hong, L.; Yuan, L.; Xu, X.; Ma, Y.; Meng, L.; Wang, J.; Zhao, N.; Wang, X.; Ma, J. Biocompatible Nanotube-Strontium/polydopamine-argonine-glycine-aspartic acid coating on Ti6Al4V enhances osteogenic properties for biomedical applications. *Micros. Res. Tech.* 2022, 85, 1518–1526. [CrossRef] [PubMed]

43. Yuan, Z.; Tao, B.; He, Y.; Liu, J.; Lin, C.; Shen, X.; Ding, Y.; Yu, Y.; Mu, C.; Liu, P.; et al. Biocompatible MoS2/PDA-RGD coating on titanium implant with antibacterial property via intrinsic ROS-independent oxidative stress and NIR irradiation. *Biomaterials* 2019, 217, 119290. [CrossRef] [PubMed]

44. Wängler, C.; Maschauer, R.; Prante, O.; Schäfer, M.; Schirrmacher, R.; Bartenstein, P.; Eisenhut, M.; Wängler, B. Multimerization of cRGD peptides by click chemistry: Synthetic strategies, chemical limitations, and influence on biological properties. *ChemBioChem* 2010, 11, 2168–2181. [CrossRef] [PubMed]

45. Prante, O.; Einsiedel, J.; Haubner, R.; Gmeiner, P.; Wester, H.-J.; Kuwert, T.; Maschauer, S. 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl Phenylthiosulfonate: A Thiol-Reactive Agent for the Chemoselective 18F-Glycosylation of Peptides. *Bioconjug. Chem.* 2007, 18, 254–262. [CrossRef] [PubMed]

46. Shekaran, A.; García, A.J. Extracellular matrix-mimetic adhesive biomaterials for bone repair. *J. Biomed. Mater. Res. Part A* 2011, 96A, 261–272. [CrossRef]

47. Dhavalikar, P.; Robinson, A.; Lan, Z.; Jenkins, D.; Chwatko, M.; Salhada, K.; Jose, A.; Kar, R.; Shoga, E.; Kannapiran, A.; et al. Review of Integrin-Targeting Biomaterials in Tissue Engineering. *Adv. Healthc. Mater.* 2020, 2020, e2000795. [CrossRef] [PubMed]

48. Parfenov, E.V.; Parfenova, L.V.; Dyakonov, G.S.; Danilko, K.V.; Mukaeva, V.R.; Farrakhov, R.G.; Lukina, E.S.; Valiev, R.Z. Surface functionalization via PEO coating and RGD peptide for nanostructured titanium implants and their in vitro assessment. *Surf. Coat. Technol.* 2019, 357, 669–683. [CrossRef]

49. Parfenova, L.V.; Lukina, E.S.; Galimshina, Z.R.; Gil’fanova, G.U.; Mukaeva, V.R.; Farrakhov, R.G.; Danilko, K.V.; Dyakonov, G.S.; Parfenov, E.V. Biocompatible Organic Coatings Based on Bisphosphonic Acid RGD-Derivatives for PEO-Modified Titanium Implants. *Molecules* 2020, 25, 229. [CrossRef]

50. Parfenov, E.; Parfenova, L.; Mukaeva, V.; Farrakhov, R.; Stotskiy, A.; Raab, A.; Danilko, K.; Rameshbabu, N.; Valiev, R. Biofunctionalization of PEO coatings on titanium implants with inorganic and organic substances. *Surf. Coat. Technol.* 2020, 404, 124868. [CrossRef]

51. Portet, D.; Denizot, B.; Rump, E.; Lejeune, J.-J.; Jallet, P. Nonpolymeric Coatings of Iron Oxide Colloids for Biological Use as Magnetic Resonance Imaging Contrast Agents. *J. Colloid Interface Sci.* 2001, 238, 37–42. [CrossRef]
52. Lecollinet, G.; Delorme, N.; Edely, M.; Gibaud, A.; Bardeau, J.F.; Hindré, F.; Boury, F.; Portet, D. Self-Assembled Monolayers of Bisphosphonates: Influence of Side Chain Steric Hindrance. *Langmuir* 2009, 25, 7828–7835. [CrossRef] [PubMed]

53. Dyakonov, G.S.; Zemtsova, E.; Mironov, S.; Semenova, I.P.; Valiev, R.Z.; Semiatin, S.L. An EBSD investigation of ultrafine-grain titanium for biomedical applications. *Mater. Sci. Eng. A* 2015, 648, 305–310. [CrossRef]

54. Nielsen, O.; Buchardt, O. Facile Synthesis of Reagents Containing a Terminal Maleimido Ligand Linked to an Active Ester. *Synthesis* 1991, 1991, 819–821. [CrossRef]

55. Ede, N.J.; Tregear, G.W.; Haralambidis, J. Routine Preparation of Thiol Oligonucleotides: Application to the Synthesis of Oligonucleotide-Peptide Hybrids. *Bioconj. Chem.* 1994, 5, 373–378. [CrossRef]

56. Parfenova, L.V.; Galimshina, Z.R.; Gil’fanova, G.U.; Alibaeva, E.I.; Danilko, K.V.; Pashkova, T.M.; Kartashova, O.L.; Farrakhov, R.G.; Mukaeva, V.R.; Parfenov, E.V.; et al. Hyaluronic acid bisphosphonates as antifouling antimicrobial coatings for PEO-modified titanium implants. *Surf. Interfaces* 2022, 28, 101678. [CrossRef]

57. He, J.; Zhou, W.; Zhou, X.; Zhong, X.; Zhang, X.; Wan, P.; Zhu, B.; Chen, W. The anatase phase of nanotopography titania plays an important role on osteoblast cell morphology and proliferation. *J. Mater. Sci. Mater. Med.* 2008, 19, 3465–3472. [CrossRef]

58. Aubakirova, V.; Farrakhov, R.; Sharipov, A.; Polyakova, V.; Parfenova, L.; Parfenov, E. Investigation of biocompatible PEO coating growth on cp-Ti with in situ spectroscopic methods. *Materials* 2022, 15, 9. [CrossRef]

59. Chen, X.; Wang, J.; Fu, B.; Yu, L. RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys. *Biochem. Biophys. Res. Commun.* 1997, 234, 594–599. [CrossRef]

60. Buckley, C.D.; Pilling, D.; Henriquez, N.V.; Parsonage, G.; Threifall, K.; Scheel-Toellner, D.; Simmons, D.L.; Akbarf, A.N.; Lord, J.M.; Salmon, M. RGD peptides induce apoptosis by direct caspase-3 activation. *Nature* 1999, 397, 534–539. [CrossRef]